# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001493152-25-019890
Filing Date
2025-10-28
Accepted
2025-10-28 16:25:07
Documents
3

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | formdefa14a.htm | DEFA14A | 28761
2 | GRAPHIC | proxy_001.jpg | GRAPHIC | 441794
3 | GRAPHIC | proxy_002.jpg | GRAPHIC | 399034
| Complete submission text file | 0001493152-25-019890.txt |  | 1188098

Mailing Address 433 PLAZA REAL SUITE 275 BOCA RATON FL 33432
Business Address 433 PLAZA REAL SUITE 275 BOCA RATON FL 33432 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-39717 | Film No.: 251425160
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)